Publication Cover
Xenobiotica
the fate of foreign compounds in biological systems
Volume 46, 2016 - Issue 10
986
Views
24
CrossRef citations to date
0
Altmetric
Clinical Pharmacokinetics and Metabolism

In vitro and in vivo characterisation of the metabolism and disposition of suvorexant in humans

, , , , , , , , , & show all
Pages 882-895 | Received 22 Oct 2015, Accepted 05 Dec 2015, Published online: 10 Feb 2016

References

  • Castro CE, Wade RS, Belser NO. (1985). Biodehalogenation: reactions of cytochrome P-450 with polyhalomethanes. Biochemistry 24:204–10
  • Chemelli RM, Willie JT, Sinton CM, et al (1999). Narcolepsy in orexin knockout mice: molecular genetics of sleep regulation. Cell 98:437–51
  • Chu X, Cai X, Cui D, et al (2013). In vitro assessment of drug-drug interaction potential of boceprevir associated with drug metabolizing enzymes and transporters. Drug Metab Dispos 41:668–81
  • Cox CD, Breslin MJ, Whitman DB, et al (2010). Discovery of the dual orexin receptor antagonist [(7R)-4-(5-chloro-1,3-benzoxazol-2-yl)-7-methyl-1,4-diazepan-1-yl][5-methy l-2-(2H-1,2,3-triazol-2-yl)phenyl]methanone (MK-4305) for the treatment of insomnia. J Med Chem 53:5320–32
  • de Lecea L, Kilduff TS, Peyron C, et al (1998). The hypocretins: hypothalamus-specific peptides with neuroexcitatory activity. Proc Natl Acad Sci USA. 95:322–7
  • Greenblatt DJ, Wright CE, von Moltke LL, et al (1998). Ketoconazole inhibition of triazolam and alprazolam clearance: differential kinetic and dynamic consequences. Clin Pharmacol Ther 64:237–47
  • Hamilton RA, Garnett WR, Kline BJ. (1981). Determination of mean valproic acid serum level by assay of a single pooled sample. Clin Pharmacol Ther 29:408–13
  • Hariparsad N, Carr B, Evers R, Chu X, et al (2008). Comparison of immortalized FaN2-4 cells and human hepatocytes as in vitro models for cytochrome P450 induction. Drug Metab Dispos 36:1046–55
  • He H, Lyons KA, Shen X, et al (2009). Utility of unbound plasma drug levels and P-glycoprotein transport data in prediction of central nervous system exposure. Xenobiotica 39:687–93
  • Herring WJ, Snyder E, Budd K, et al (2012). Orexin receptor antagonism for treatment of insomnia: a randomized clinical trial of suvorexant. Neurology 79:2265–74
  • Kuhl PW. (1994). Excess-substrate inhibition in enzymology and high-dose inhibition in pharmacology: a reinterpretation [corrected]. Biochem J 298: 171–80
  • Lin Y, Lu P, Tang C, et al (2001). Substrate inhibition kinetics for cytochrome P450-catalyzed reactions. Drug Metab Dispos 29:368–74
  • Michelson D, Snyder E, Paradis E, et al (2014). Safety and efficacy of suvorexant during 1-year treatment of insomnia with subsequent abrupt treatment discontinuation: a phase 3 randomised, double-blind, placebo-controlled trial. Lancet Neurol 13:461–71
  • Prueksaritanont T, Chu X, Gibson C, et al (2013). Drug-drug interaction studies: regulatory guidance and an industry perspective. AAPS J 15:629–45
  • Sakurai T, Amemiya A, Ishii M, et al (1998). Orexins and orexin receptors: a family of hypothalamic neuropeptides and G protein-coupled receptors that regulate feeding behavior. Cell 92:573–85
  • Sun H, Kennedy WD, Lewis N, et al (2012). The single dose pharmacokinetic (PK) and pharmacodynamic (PD) profiles of suvorexant (MK-4305); a dual orexin receptor antagonist, in healthy male subjects. Clin Pharmacol Ther 91:S29
  • Sun H, Kennedy WD, Lewis N, et al (2011). The single dose pharmacokinetic (PK) and pharmacodynamic (PD) profiles of suvorexant (MK-4305), a dual orexin receptor antagonist, in healthy male subjects. Sleep Biol Rhythms 9:332 [abs PO-1-235]
  • Winrow CJ, Gotter AL, Cox CD, et al (2011). Promotion of sleep by suvorexant-a novel dual orexin receptor antagonist. J Neurogenet 25:52–61
  • Winrow CJ, Renger JJ. (2014). Discovery and development of orexin receptor antagonists as therapeutics for insomnia. Br J Pharmacol 171:283–93
  • Zhao P, Ragueneau-Majlessi I, Zhang L, et al (2009). Quantitative evaluation of pharmacokinetic inhibition of CYP3A substrates by ketoconazole: a simulation study. J Clin Pharmacol 49:351–9

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.